Department of Orthopedics Surgery, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China.
Department of Orthopaedic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Adv Sci (Weinh). 2024 Sep;11(36):e2404080. doi: 10.1002/advs.202404080. Epub 2024 Jul 23.
The molecular mechanism underlying abnormal osteoclastogenesis triggering subchondral bone remodeling in osteoarthritis (OA) is still unclear. Here, single-cell and bulk transcriptomics sequencing analyses are performed on GEO datasets to identify key molecules and validate them using knee joint tissues from OA patients and rat OA models. It is found that the catalytic subunit of protein phosphatase 2A (PP2Ac) is highly expressed during osteoclastogenesis in the early stage of OA and is correlated with autophagy. Knockdown or inhibition of PP2Ac weakened autophagy during osteoclastogenesis. Furthermore, the ULK1 expression of the downstream genes is significantly increased when PP2Ac is knocked down. PP2Ac-mediated autophagy is dependent on ULK1 phosphorylation activity during osteoclastogenesis, which is associated with enhanced dephosphorylation of ULK1 Ser637 residue regulating at the post-translational level. Additionally, mTORC1 inhibition facilitated the expression level of PP2Ac during osteoclastogenesis. In animal OA models, decreasing the expression of PP2Ac ameliorated early OA progression. The findings suggest that PP2Ac is also a promising therapeutic target in early OA.
在骨关节炎 (OA) 中,触发软骨下骨重塑的破骨细胞异常发生的分子机制尚不清楚。在这里,对 GEO 数据集进行单细胞和批量转录组测序分析,以鉴定关键分子,并使用 OA 患者的膝关节组织和大鼠 OA 模型进行验证。结果发现,蛋白磷酸酶 2A 的催化亚基 (PP2Ac) 在 OA 早期破骨细胞发生过程中高表达,与自噬相关。敲低或抑制 PP2Ac 会削弱破骨细胞发生过程中的自噬。此外,当 PP2Ac 被敲低时,下游基因的 ULK1 表达显著增加。PP2Ac 介导的自噬依赖于破骨细胞发生过程中 ULK1 的磷酸化活性,这与在翻译后水平调节 ULK1 Ser637 残基去磷酸化增强有关。此外,mTORC1 抑制促进了破骨细胞发生过程中 PP2Ac 的表达水平。在动物 OA 模型中,降低 PP2Ac 的表达可改善早期 OA 的进展。这些发现表明 PP2Ac 也是早期 OA 有前途的治疗靶点。
Oxid Med Cell Longev. 2021
Biochem Biophys Res Commun. 2018-6-29
Nat Commun. 2015-8-27
Nucleic Acids Res. 2023-1-6
Pharmaceuticals (Basel). 2021-12-20
Front Mol Biosci. 2021-7-28
Nat Med. 2020-8-17